Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVD regimen for newly diagnosed multiple myeloma with renal impairment
ChiCTR2200066618Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib, doxorubicin and dexamethasone in multiple myeloma (MM) and chronic kidney disease (CKD), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoint: objective response rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
bortezomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2200066618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066618.